Stephen Mandel Blueprint Medicines Corp Call Options Transaction History
Lone Pine Capital LLC
- $12.9 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BPMC
# of Institutions
351Shares Held
60.3MCall Options Held
2.25MPut Options Held
1.18M-
Vanguard Group Inc Valley Forge, PA6.68MShares$580 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.65MShares$577 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.39MShares$468 Million0.06% of portfolio
-
Wellington Management Group LLP Boston, MA3.96MShares$344 Million0.07% of portfolio
-
State Street Corp Boston, MA2.77MShares$240 Million0.01% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $5.18B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...